PRVL Prevail Therapeutics Inc

Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today announced that Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer, will present at the Morgan Stanley 2019 Global Healthcare Conference on Wednesday, September 11, 2019 at 1:00 p.m. ET in New York City.

The live webcast will be available in the investor section of the company's website at www.prevailtherapeutics.com. The webcast will be archived for 90 days following the presentation.

About Prevail TherapeuticsPrevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. Prevail was founded by Dr. Asa Abeliovich in 2017, through a collaborative effort with The Silverstein Foundation for Parkinson’s with GBA and OrbiMed, and is headquartered in New York, NY.

Media Contact:
Katie Engleman
1AB 
katie@1ABmedia.com

Investor Contact:
investors@prevailtherapeutics.com